Spread of malaria continues to trump Zika concern

Saturday, Feb 13, 2016 @ 12:13pm by BioPrepWatch Reports

The spread of the Zika virus has been alarming, but the real issue stems from the source of the spreading: the Aedes aegypti mosquito.
Read More »

News source for infectious disease professionals to provide all-digital information

Thursday, Feb 11, 2016 @ 6:05pm by BioPrepWatch Reports

Michael J. Hennessy Associates Inc. recently launched Contagion, a news resource designed for medical professionals that work with infectious diseases.
Read More »

Merck's Ebola vaccine candidate to be evaluated by WHO

Tuesday, Dec 29, 2015 @ 11:17am by BioPrepWatch Reports

An Ebola virus vaccine candidate from Merck will be reviewed by the World Health Organization (WHO).
Read More »

Arno’s AR-12 antimicrobial drug shows promise against myriad pathogens

Friday, Oct 9, 2015 @ 4:22pm by BioPrepWatch Reports

Promising data recently released on the AR-12 antimicrobial drug from Arno Therapeutics demonstrates that the drug has substantial potential as a new and novel therapeutic agent against infectious diseases.
Read More »

Arno's AR-12 antimicrobial drug data shows positive results

Tuesday, Sep 22, 2015 @ 10:41am by BioPrepWatch Reports

Arno Therapeutics Inc. released promising data from its AR-12 antimicrobial drug at the Interscience Conference of Antimicrobial Agents and Chemotherapy/International Congress of Chemotherapy (ICAAC/ICC) and Infection 2015 presentation Saturday.
Read More »

Johnson & Johnson company awarded $28.5 million for ebola vaccine development

Sunday, Sep 20, 2015 @ 1:19pm by BioPrepWatch Reports

New Jersey-based Johnson & Johnson officials recently announced that one of its Janssen Pharmaceutical companies, Crucell Holland B.V., was awarded $28.5 million from The Biomedical Advanced Research and Development Authority (BARDA).
Read More »

Four Arno to present 4 abstracts at San Diego conference

Monday, Sep 14, 2015 @ 7:23pm by BioPrepWatch Reports

Arno Therapeutics, Inc. said Monday that four abstracts regarding its AR-12 candidate antimicrobial drug have been selected for presentation at the Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and the International Congress of Chemotherapy and Infection (ICC) 2015.
Read More »

Soligenix CEO discusses biodefense activity with DDNews

Friday, Sep 11, 2015 @ 8:39pm by BioPrepWatch Reports

Soligenix Inc. CEO and President Christopher Schaber recently gave an interview with DDNews during which he discussed the company's therapeutics and biological defense business activities.
Read More »

Soligenix awarded additional ricin vaccine funding

Thursday, Aug 20, 2015 @ 6:15pm by BioPrepWatch Reports

Soligenix, Inc. has received an additional $2.7 million from the National Institute of Allergy and Infectious Diseases (NIAID) in order to continue development of their ricin vaccine, the company announced Wednesday.
Read More »

Soligenix agrees to $10 million equity agreement

Monday, Aug 3, 2015 @ 3:37pm by BioPrepWatch Reports

Soligenix, Inc. announced on Monday that it has entered into an equity purchase agreement with Kodiak Capital Group,LLC; River North Equity, LLC and Kingsbrook Opportunities Master Fund LP.
Read More »

Ex-CDC division chief appointed to VaxInnate board

Thursday, Jun 18, 2015 @ 1:46pm by BioPrepWatch Reports

VaxInnate Corp. said Wednesday that former Centers for Disease Control and Prevention (CDC) Division Chief Thomas Monath has been named to its board of directors.  Monath is CSO and COO of BioProtection Systems, which has a partnership to develop a vaccine candidate for the Ebola virus with Merck.
Read More »

Arno Therapeutics and U.S. Army researchers to study antiviral effects of AR-12

Thursday, Jun 4, 2015 @ 4:52pm by BioPrepWatch Reports

Arno Therapeutics, Inc. said Wednesday that it has entered into a cooperative research and development agreement and material transfer agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study the antiviral effects of AR-12. Arno Therapeutics, a Flemington, New Jersey-based biopharmaceutical firm that focuses on the development of therapeutic agents to treat patients with cancer and other potentially fatal diseases, and the Army research institute will study the
Read More »

DRS signs partnership agreement with Beth-El Industries

Wednesday, Apr 1, 2015 @ 3:26pm by BioPrepWatch Reports

Companies team up to produce CBRN protection systems for combat situations.
Read More »

NewLink to get $20 million in Ebola vaccine research milestone

Friday, Feb 20, 2015 @ 5:44pm by BioPrepWatch Reports

NewLink Genetics said on Thursday that it had reached a milestone in its development of an Ebola vaccine, and will receive a $20 million payment as a result. The milestone, listed in a license and collaboration agreement with Merck, came out of initiating a clinical trial for the rVSV-EBOV vaccine that the two companies are developing.
Read More »

BARDA extends VaxInnate contract with $53 million deal

Thursday, Feb 19, 2015 @ 3:18pm by BioPrepWatch Reports

VaxInnate's contract with the Biomedical Advanced Research and Development Authority (BARDA) has been extended to include the creation of two new influenza vaccines through the clinical trial process, they announced Thursday.
Read More »

NewLink Genetics subsidiary awarded $30 million contract for Ebola vaccine

Tuesday, Dec 23, 2014 @ 9:40am by BioPrepWatch Reports

The Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services awarded a $30 million contract to BioProtection Systems for the manufacturing and development of the investigational rVSV-EBOV Ebola vaccine.
Read More »